CUSIP No. 185063 10 4
Page 15 of 20
This Amendment No. 6 on Schedule 13D amends the statement on Schedule 13D, dated June 7, 2016, which relates to the Common Stock, par value $0.001 per share (the “Common Stock”) of Clearside Biomedical, Inc. (the “Issuer”) which was previously amended on Schedule 13D/A, dated January 20 and April 17, 2017, March 21, 2018 and July 17 and December 4, 2019 filed by:
Hatteras Venture Advisors III, LLC (“HVA III”)
Hatteras Venture Partners III, LP (“HVP III”)
Hatteras Venture Affiliates III, LP (“HV Affiliates”)
Hatteras Venture Advisors IV SBIC, LLC (“HVA SBIC”)
Hatteras Venture Partners IV SBIC, LP (“HVP SBIC”)
Hatteras Venture Advisors IV, LLC (“HVA IV”)
Hatteras Venture Partners IV, LP (“HVP IV”)
Hatteras NC Fund, LP (“Hatteras Fund”)
John C. Crumpler
Robert A. Ingram
Kenneth B. Lee
Clay B. Thorp
Douglas Reed
(collectively, the “Reporting Persons”).
Except as expressly amended below, the Schedule 13D, dated June 7, 2016, remains in effect.
Item 5. | Interest in Securities of the Issuer. |
(a) | Aggregate number and percentage beneficially owned: |
HVA III — 0 or 0%
HVP III — 0 or 0%
HV Affiliates — 0 or 0%
HVA SBIC— 3,055,052 or 5.1%
HVP SBIC — 3,055,052 or 5.1%
HVA IV— 489,988 or less than 1%
HVP IV — 387,475 or less than 1%
Hatteras Fund— 102,513 or less than 1%
John C. Crumpler — 3,550,214 or 5.9%
Robert A. Ingram — 3,555,302 or 5.9%
Kenneth B. Lee — 3,550,214 or 5.9%
Clay B. Thorp — 3,654,062 or 6.1%
Douglas Reed — 3,551,432 or 5.9%
| (b) | Number of shares as to which the person has: |
| (i) | Sole power to vote or to direct the vote |
HVA III — 0
HVP III — 0
HV Affiliates — 0
HVA SBIC— 0